-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $58

Benzinga·05/08/2026 12:58:44
Listen to the news
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $68 to $58.